Research and Markets: Epiomic Epidemiology Series: Fabry Disease Forecast in 8 Major Markets 2015-2025

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/zf3l5c/epiomic) has announced the addition of the "Epiomic Epidemiology Series: Fabry Disease Forecast in 8 Major Markets 2015-2025" report to their offering.

Fabry disease is a lysosomal storage disorder, caused by a genetic defect in the alpha-galactosidase-A gene (aGLA-gene), localized on the long arm of the X-chromosome (Xq22). This gene is essential in the breakdown of fatty substances, otherwise substances like globotriaosylceramide, will accumulate in the arteries, narrowing them and reducing blood flow around the body. It is a multi-system disorder characterised by dermatologic angiokeratoma corporis diffusum and purpura haemorrhagica nodularis, but also affects ocular, auditory, cardiac, digestive and renal systems.

This report provides the current prevalent population for Fabry Disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the publisher's own analysis team, several of the main symptoms and co-morbidities of Fabry disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

- Angiokeratoma

- Cornea verticillata (corneal whorling)

- Hearing loss

- Tinnitus

- Proteinurea

- Cardiac hypertrophy & arrhythmias

- Sweating dysfunction

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis &Clinical Course

7. Key Co-morbid Conditions /Features Associated with the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Prevalence for Fabry Disease

10. Hearing Loss in Fabry Disease

11. Associated Co-morbid Conditions of Fabry Disease

12. Abbreviations and Acronyms used in the Report

13. Other Publications

14. Online Patient-Based Databases

15. Patient-Based Offering

16. Online Pricing Data and Platforms

17. References

18. Appendix

For more information visit http://www.researchandmarkets.com/research/zf3l5c/epiomic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals